topotecan + lurbinectedin + amrubicin

topotecan + lurbinectedin + amrubicin is an investigational combination of three small-molecule antineoplastic agents, each with a distinct but complementary mechanism of action targeting various aspects of DNA function in cancer cells. - **Topotecan** is a topoisomerase I inhibitor that interferes with DNA replication by stabilizing the DNA-topoisomerase I complex, resulting in DNA damage during replication. - **Lurbinectedin** is a synthetic marine-derived selective inhibitor of oncogenic transcription that binds to select guanine residues in DNA, causing degradation of RNA polymerase II and inhibiting transcription in tumor cells. - **Amrubicin** is a third-generation synthetic anthracycline and a specific inhibitor of topoisomerase II, exerting its cytotoxic effect through DNA intercalation and inhibition of DNA replication, transcription, and repair, leading to cell death. All three drugs are primarily investigated for the treatment of small cell lung cancer (SCLC), particularly in patients who have relapsed after platinum-based chemotherapy. This combination regimen is not yet an approved therapy; current data for multi-drug strategies in this space mainly include combinations of these drugs with other agents (not all three together in a single standardized regimen). Each constituent drug has demonstrated activity in SCLC and other advanced malignancies[2][3][4][6][8][9].